When Progress Looks Like a Daily Pill: The Complex Reality of Vorasidenib

The Momentum

Vorasidenib, marketed by Servier Pharmaceuticals, was approved based on the INDIGO trial, a phase 3 study of 331 adults with grade 2 IDH1/2-mutant diffuse glioma who had undergone surgery but not yet received radiation or chemotherapy.

The results were striking: patients taking vorasidenib had a median progression-free survival (life with stable disease, meaning no progression) of 27.7 months, compared to 11.1 months for those on placebo – no medication (NEJM, 2023).

The risk of disease progression or death was reduced by 61%. The time to next treatment (meaning how long patients could avoid radiation or chemotherapy) was not reached in the vorasidenib group, versus 17.8 months in the placebo group.

For a population often in their 30s and 40s, many working, raising families, and leading active lives, this was monumental and highly anticipated. The drug’s once-daily oral dose meant treatment could be done at home instead of in an infusion center.

“Prior to vorasidenib approval, I was using vorasidenib in certain patients with IDH mutations, but the data really has helped a lot in terms of clarifying which patients I should be trying it in which patients we do not have information on,” explains Dr. Sharma.

The Reality of a Daily Therapy

Despite its convenience and promises, vorasidenib introduces a new kind of psychological and logistical burden. Many patients are accustomed to finite treatment courses: chemotherapy that ends after six cycles or radiation lasting a few weeks, and this is the path of the majority of treatment they have taken in their life for other illness issues. Vorasidenib, by contrast, is indefinite.

That means taking a pill every day for years, with regular monitoring, and without a clear endpoint. Patients often ask the same questions: How long will I need this? Will it always work? Will my insurance keep covering it?

According to the INDIGO study and post-approval experience, adherence rates are high, but treatment interruptions are common. About 20% of patients in the trial required dose interruptions or reductions due to side effects, most commonly liver enzyme elevations (referred to as hepatotoxicity).

“We are still learning in terms of how to manage the hepatotoxicity that comes with it,” she says. “Everyone has done different things. Some people have completely stopped the drug, some have given a break and restarted it. And so we are still learning different practices around it.”

Balancing Hope With Uncertainty

The benefits of vorasidenib are clear: for most patients, the tumor stays quiet far longer than it would without therapy. But the long-term unknowns are also real. Because this is a new drug, no one yet knows what 10 or 15 years of continuous use might look like, whether resistance will emerge, or whether chronic use could have subtle effects not yet detected.

“We really don’t know what patients will learn 10 to 15 years out.” the doctor admits. “That’s why I encourage my patients when they are considering starting Vorasidenib to do the same, to go out there, join the support groups online, or join the different Facebook groups and learn more about the experience of these patients.”

Patients are increasingly turning to online support groups and communities,on platforms like Facebook or the American Brain Tumor Association’s (ABTA) forums, to connect with others on vorasidenib. Hearing from people who have been on the medication for a year or more often helps patients manage the uncertainty and normalize the commitment.

Living With an Invisible Treatment

One paradox of vorasidenib therapy is that patients often feel physically well, sometimes even completely normal, while taking it. Unlike chemotherapy, it doesn’t cause hair loss, nausea, or fatigue for most people. But that very normalcy can make the psychological side unbalanced. The daily pill is a reminder that the disease is still there, quietly managed but not gone.

Some patients describe the experience as living with an “invisible illness”,healthy on the outside, but carrying an internal vigilance that never quite lifts. For many, building a routine and a sense of control—tracking doses, marking milestones, or connecting with peers—helps transform the indefinite into something sustainable.

Questions to Ask Your Doctor

• If I have to pause treatment due to liver changes, what’s the plan for restarting safely?
• What financial or patient-assistance programs are available if insurance coverage changes?
• If I have to pause treatment due to financial concerns, what are my options?
• What can I do mitigate the burden of the treatment?

Learn more about SurvivorNet's rigorous medical review process.